Tanja F.
- Country
- Germany
- Department
- 04905: Klinik für Frauenheilkunde und Geburtshilfe
Research Overview
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009)
- Comparison of Adjuvant Elacestrant with Standard Endocrine Therapy in High-Risk ER+/HER2- Early Breast Cancer
Data & Insights
Has run more than one trial at 443 of 866 partner sites.
Specializations
Breast Cancer Research
Specializes in various forms of breast cancer treatment, particularly focusing on HER2-positive, HER2-negative, and triple-negative breast cancer therapeutic approaches.
- Advanced and Metastatic Disease Management
- Hormone Receptor-Positive Disease Treatment
- Novel Therapeutic Combinations
Investigates innovative treatment strategies including targeted therapies and immunotherapy combinations.
Gynecologic Oncology
Focuses on treating various gynecologic cancers with particular emphasis on epithelial ovarian cancer and advanced disease management.
- Ovarian Cancer Maintenance Therapy
- Endometrial Cancer Treatment
- Vulvar Cancer Interventions
Explores combination approaches using targeted therapies and immunotherapy in gynecologic malignancies.
Therapeutic Innovation
Leads research in novel therapeutic approaches including targeted molecular therapies and immunotherapy combinations.
- Maintenance Treatment Strategies
- Combination Therapy Development
- Treatment Resistance Management
Investigates personalized treatment approaches based on specific genetic and molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.